Physician profile
Vinay Nagaraj
NPI 1952585424
$9,253.97
in general payments reported to CMS, 2019-2025
30 companies · $1,508 in 2025
The $1,508 reported for 2025 was more than what 86% of Addiction Psychiatry providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,316 · 2020: $522 · 2021: $1,706 · 2022: $1,703 · 2023: $1,625 · 2024: $874 · 2025: $1,508.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,007.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,007.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,110.48 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,096.38 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $1,016.35 | 2019-2025 | Spravato, Invega Sustenna |
| Alkermes, INC. | $838.04 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Lundbeck LLC | $600.41 | 2019-2025 | Rexulti, Abilify Maintena |
| Otsuka America Pharmaceutical, INC. | $596.92 | 2019-2025 | Rexulti, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $417.53 | 2019-2025 | Trintellix |
| Sunovion Pharmaceuticals INC. | $404.29 | 2019-2022 | |
| Corium, LLC | $385.73 | 2021-2025 | Azstarys |
| Tris Pharma INC | $338.05 | 2020-2025 | Dyanavel Xr |
| Teva Pharmaceuticals USA, INC. | $329.08 | 2019-2025 | Austedo, Austedo Xr, Uzedy |
| Ironshore Pharmaceuticals INC. | $292.45 | 2019-2024 | Jornay Pm |
| Neurocrine Biosciences, INC. | $233.63 | 2019-2023 | Ingrezza |
| Neos Therapeutics, Lp | $231.02 | 2019-2023 | Adzenys Xr-Odt |
| Supernus Pharmaceuticals, INC. | $214.96 | 2021-2024 | Qelbree, Qelbree |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $204.65 | 2019-2020 | |
| Axsome Therapeutics, INC. | $118.57 | 2023-2025 | Auvelity |
| Collegium Pharmaceutical, INC. | $109.09 | 2025 | Jornay Pm |
| Avanir Pharmaceuticals, INC. | $105.00 | 2019 | |
| Vanda Pharmaceuticals INC. | $93.39 | 2025 | Fanapt, Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $89.26 | 2024-2025 | Cobenfy |
| Adlon Therapeutics L.P. | $76.67 | 2019-2021 | |
| Bausch Health US, LLC | $75.61 | 2021-2024 | Wellbutrin, Aplenzin |
| Jazz Pharmaceuticals INC. | $59.02 | 2021 | |
| Noven Therapeutics, LLC | $57.15 | 2023-2025 | Secuado, Xelstrym |
| Eisai INC. | $55.54 | 2021 | |
| Vertical Pharmaceuticals, LLC | $40.75 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $30.97 | 2022 | |
| Shire North American Group INC | $17.87 | 2019 | |
| Alfasigma USA, INC. | $15.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vinay Nagaraj listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.